Advances in the Diagnosis and Management of Pulmonary Hypertension

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Acquired Cardiovascular Disease".

Deadline for manuscript submissions: closed (28 February 2025) | Viewed by 829

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medicine II, Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria
Interests: pulmonary arterial hypertension; chronic thromboembolic pulmonary hypertension
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Guidelines summarize and evaluate evidence and should facilitate decision-making for health professionals. Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and be associated with a variety of cardiovascular and respiratory diseases. The management of PH patients is complex, requiring a multifaceted, holistic, and multidisciplinary approach. Still, there are some unanswered topics that should be discussed, including the following:

  • New hemodynamic definition of PH and its clinical implications.
  • How can we detect PH earlier?
  • What is new in the treatment algorithm of PH?
  • How do we treat PH associated with left heart disease (PH-LHD)?
  • CTEPH: ways to cure PH.
  • How do we treat PH due to lung disease/hypoxia?
  • Pregnancy and PAH.
  • New standards.

Dr. Nika Skoro-sajer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonary arterial hypertension
  • hemodynamic definition
  • pulmonary hypertension

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 334 KiB  
Review
Hemodynamic Definitions, Phenotypes, Pathophysiology, and Evaluation of Pulmonary Hypertension Related to Left Heart Disease
by Elizabeth C. Ghandakly, Akshat Banga and Roop Kaw
J. Cardiovasc. Dev. Dis. 2025, 12(7), 238; https://doi.org/10.3390/jcdd12070238 - 22 Jun 2025
Viewed by 497
Abstract
Pulmonary hypertension (PH) can develop from multiple etiologic mechanisms and disease states. Of all such conditions, left-sided heart disease (LHD) is commonly understood to be the most common etiology or mechanism. Given the widespread prevalence of left heart disease and the prognostic implications [...] Read more.
Pulmonary hypertension (PH) can develop from multiple etiologic mechanisms and disease states. Of all such conditions, left-sided heart disease (LHD) is commonly understood to be the most common etiology or mechanism. Given the widespread prevalence of left heart disease and the prognostic implications of PH, early diagnosis is imperative. More recently, the diagnostic cut-offs for mean pulmonary arterial pressure as well as peripheral vascular resistance have been lowered to achieve this objective. Despite these revised standards, the current indications for right heart catheterization are mostly aimed at identifying advanced disease. Proven vasodilator therapies for pulmonary arterial hypertension have so far not shown a meaningful role in the management of PH in LHD. This is largely related to the fact that multiple mechanisms and co-morbidities can independently lead to the development of PH in an individual patient. Understanding and identifying those phenotypes remain important in devising future treatment strategies. Molecular pathways that eventually lead to irreversibility of PH can provide another frontier in the pharmacologic management of PH in LHD. Full article
(This article belongs to the Special Issue Advances in the Diagnosis and Management of Pulmonary Hypertension)
Show Figures

Graphical abstract

Back to TopTop